Evidence map›Paper›PMID 30664764›Full record

ArticleNature immunology2019

Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle.

Wan-Chen Cheng, Yao-Chen Tsui, Simone Ragusa, Viktor H Koelzer, Marco Mina, Fabien Franco, Heinz Läubli, Benjamin Tschumi, Daniel Speiser, Pedro Romero and 5 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Nature immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Deciphering Uncoupling Proteins in Cellular Homeostasis and Metabolic Health.International journal of biological sciences · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Epicatechin DecreasesInternational journal of molecular sciences · 2025
    Article
  11. Review
  12. Article
  13. Leveraging T cells for cancer immunotherapy.Immunity & inflammation · 2025
    Review
  14. Article
  15. Article
  16. Differential regulation of mitochondrial uncoupling protein 2 in cancer cells.Biochimica et biophysica acta. Bioenergetics · 2024
    Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Wan-Chen ChengDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.
Yao-Chen TsuiDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.
Simone RagusaDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.
Viktor H KoelzerInstitute of Pathology, Cantonal Hospital Baselland, Liestal, Switzerland.ORCID http://orcid.org/0000-0001-9206-4885
Marco MinaDepartment of Computational Biology, University of Lausanne, Lausanne, Switzerland.
Fabien FrancoDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.
Heinz LäubliDepartment of Biomedicine, University Hospital Basel, Basel, Switzerland.
Benjamin TschumiDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.
Daniel SpeiserDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.
Pedro RomeroDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.
Alfred ZippeliusDepartment of Biomedicine, University Hospital Basel, Basel, Switzerland.
Tatiana V PetrovaDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.
Kirsten MertzInstitute of Pathology, Cantonal Hospital Baselland, Liestal, Switzerland.
Giovanni CirielloDepartment of Computational Biology, University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-2021-8683
Ping-Chih HoDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland. ping-chih.ho@unil.ch.ORCID http://orcid.org/0000-0003-3078-3774
Ludwig Cancer Research · CHSIB Swiss Institute of Bioinformatics · CHUniversity Hospital of Basel · CHUniversity Hospital of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint blockade therapy has shifted the paradigm for cancer treatment. However, the majority of patients lack effective responses due to insufficient T cell infiltration in tumors. Here we show that expression of mitochondrial uncoupling protein 2 (UCP2) in tumor cells determines the immunostimulatory feature of the tumor microenvironment (TME) and is positively associated with prolonged survival. UCP2 reprograms the immune state of the TME by altering its cytokine milieu in an interferon regulatory factor 5-dependent manner. Consequently, UCP2 boosts the conventional type 1 dendritic cell- and CD8

Indexed as

AnimalsAntineoplastic Agents, ImmunologicalCD8-Positive T-LymphocytesCell Line, TumorDendritic CellsDrug Resistance, NeoplasmFemaleHumansImmunotherapyInterferon Regulatory FactorsMelanoma, ExperimentalMice, Inbred C57BLProgrammed Cell Death 1 ReceptorSkin NeoplasmsSurvival AnalysisTreatment OutcomeAntineoplastic Agents, ImmunologicalInterferon Regulatory FactorsIrf5 protein, mouseProgrammed Cell Death 1 ReceptorUcp2 protein, mouseUncoupling Protein 2

Identifiers

PMID30664764
OpenAlexW2910579854

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.